rhBMP-2用于腰椎椎体间融合时，剂量越大，脊神经炎等并发症越高。组织工程技术为减少rhBMP-2剂量提供了可能。本课题拟利用KLD-12多肽支架材料药物缓释的特性，复合rhBMP-2，构建KLD-12多肽/ rhBMP-2纳米纤维凝胶。以新西兰大白兔及绵羊为研究对象，体外KLD-12多肽/ rhBMP-2凝胶三维培养BMSCs二周。体内将KLD-12多肽/ rhBMP-2/BMSCs植入绵羊腰椎椎体间隙。应用大体观察、AFM、组织化学染色、免疫荧光染色、RT-PCR、X线、CT等技术，研究：1）KLD-12多肽/ rhBMP-2凝胶诱导异位成骨的生物活性；2）KLD-12多肽/ rhBMP-2凝胶诱导BMSCs向成骨细胞分化的生物活性；3）KLD-12多肽/ rhBMP-2/BMSCs凝胶诱导异位成骨活性及用于腰椎椎体间融合的效果。为治疗椎间盘晚期退变及腰椎不稳寻找新的微创治疗方案。

When used rhBMP-2 in lumbar interbody fusion, the complications as postoperative radiculitis associated with rhBMP-2 dose were higher. Tissue engineer offers the possibility to reduce the rhBMP-2 dose. This project intends to composite rhBMP-2 and builds KLD-12 peptide/rhBMP-2 nano-fiber hydrogel by taking advantage of the characteristics of the KLD-12 peptide scaffold materials for drug delivery. The New Zealand rabbits and local sheep are employed as experimental animals, BMSCs is cultured in the KLD-12 peptide/rhBMP-12 hydrogel for two weeks in vitro. The KLD-12 peptide/rhBMP-12/BMSCs are implanted in sheep lumbar vertebral body gap in vivo. General observation, AFM, Histochemical staining, Immunofluorescence staining, RT-PCR, X-ray and CT will be employed to study: 1) KLD-12 peptide/rhBMP-12 hydrogel-induced biological activity of the ectopic bone formation; 2) KLD-12 peptide/rhBMP-12 hydrogel-induced biological activity of BMSCs to differentiate into osteoblasts; 3) KLD-12 peptide/rhBMP-12 /BMSCs hydrogel-induced biological activity of the ectopic bone formation and the effect in lumbar interbody fusion. The object is to seek a new minimally invasive treatment options for intervertebral disc degeneration and lumbar instability.